NoviThera ApS ("NoviThera"), a majority owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD) ("Nordicus" or the "Company"), a financial ...
NoviThera ApS (“NoviThera”), a majority owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic ...
This review outlines the emerging role of Interleukin-26 in autoimmune disease biology and describes a possible diagnostic and therapeutic signal for patient monitoring and future stratification.
A Czech scientist has contributed to understanding the function of the thymus—the training center of the immune system. T ...
“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” “Our ...
Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes. Detection of ...
An expert discusses how the diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) require careful recognition of characteristic dermatologic and hematologic features, with ...
BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback